A series of new studies reveals a higher European prevalence of atopic dermatitis (AD) than that reported in the United States, and a hefty burden including lost school and workdays for patients and parents. Because AD burden was found to be higher in adolescents than in adults, researchers add, adolescents with moderate-to-severe disease may face an even greater unmet therapeutic need.
Over the years, studies have examined patient-reported AD burden either in clinical cohorts that may not be generalizable, or population-based cohorts in children or adults, says Jonathan Silverberg, M.D., Ph.D., MPH, director of clinical research, director of patch testing and an associate professor of dermatology at The George Washington University School of Medicine and Health Sciences.
"A group that has not been studied well to date has been the adolescent population. There's been a substantial amount of epidemiology work done in the adolescent age group from the ISAAC study, ages 13 to 14 years. Aside from that, we don't have great data on burden of disease in older children and adolescents,” he says. “In addition, most studies of AD in childhood and adolescence used disparate methodology, which precludes the ability to compare results with studies of adult AD."
The 1377-patient Epidemiology of Children with Atopic Dermatitis Reporting on Their Experience (EPI-CARE) study is part of a large multinational study that examined AD across the entire life course. Between September 2018 and February 2019, investigators conducted a web-based survey of adolescents aged 12 to 17 years with AD in the United States, France, Germany, Italy, Spain and the UK. Average respondent age was 15 years, with a roughly even proportion of males and females at varying degrees of disease severity.
In one poster,1 Silverberg et al. reported a European AD prevalence of 14.7%, versus 9.3% in the United States. European prevalence rates ranged from 8.7% in Germany to 19.8% in Spain. Regional differences regarding climate and genetics may account for the higher overall prevalence in Europe, says Dr. Silverberg.
Dr. Silverberg has received honoraria as a speaker/consultant for Galderma, Abbvie, AnaptysBio, Asana BioSciences, Arena, Boehringer-Ingelheim, Dermavant, Eli Lilly, GlaxoSmithKline, Glenmark, Kiniksa, Leo, Menlo, Novartis, Pfizer, and Regeneron-Sanofi and has received grants as an investigator from Galderma and GlaxoSmithKline.
1. Silverberg JI, Barbarot S, Simpson EL, et al. Epidemiology of atopic dermatitis in the adolescent population: a cross-sectional study in the United States and Europe. Poster P1458. European Academy of Dermatology and Venereology Congress; October 9-13, 2019. Madrid, Spain.
2. Weidinger S, Simpson EL, Silverberg JI, et al. The patient-reported disease burden in adolescents with atopic dermatitis: a cross-sectional study in the United States and Europe. Poster P1459. European Academy of Dermatology and Venereology Congress; October 9-13, 2019. Madrid, Spain.
3. Girolomoni G, Gadkari A, Auziere S, et al. Characterizing the patient-reported disease burden in adults with atopic dermatitis: a cross-sectional study from clinical practices in Europe and Canada. Poster P0253. European Academy of Dermatology and Venereology Congress; September 12-16, 2018. Paris, France.